Bristol-Myers Squibb Co. - BMY STOCK NEWS

Bristol Myers Squibb (NYSE: BMY) presented six-and-a-half-year results from the CheckMate -067 trial, showing significant survival benefits for patients with advanced melanoma treated with Opdivo (nivolumab) plus Yervoy (ipilimumab). The median overall survival was reported at 72.1 months for the combination therapy, the longest in a Phase 3 trial for this condition. Progression-free survival rates were 34% for the combination, compared to 29% and 7% for Opdivo and Yervoy alone, respectively. Safety profiles remained consistent with past studies, indicating sustained benefits of the treatment regimen.

Bristol Myers Squibb (BMY) and bluebird bio (BLUE) revealed new findings from the pivotal KarMMa study on Abecma (idecabtagene vicleucel), a CAR T cell therapy for multiple myeloma. Updated results show a consistent overall response rate of 73% and a complete response in 33% of patients after a median follow-up of 24.8 months. The safety profile indicates common adverse events include cytopenias (97%) and cytokine release syndrome (84%). Abecma remains the first BCMA-directed CAR T therapy approved by the FDA, with ongoing reviews in other regions.

Bristol Myers Squibb (NYSE: BMY) announced promising results from the Phase 2/3 RELATIVITY-047 trial, demonstrating that the combination of relatlimab and nivolumab significantly improved progression-free survival (PFS) in patients with untreated metastatic melanoma compared to Opdivo alone. The median PFS was 10.12 months for the combination versus 4.63 months for Opdivo (p=0.0055). This regimen is the first to show a statistical benefit over anti-PD-1 therapy in this patient group. The safety profile was consistent with previous studies, highlighting its potential as a new treatment option.

Bristol-Myers Squibb (BMY) has secured a global exclusive license for Agenus' bispecific antibody AGEN1777, targeting TIGIT. The deal entails a $200 million upfront payment and additional potential milestones totaling up to $1.36 billion, plus royalties on sales. AGEN1777, designed to enhance anti-tumor activities, is currently in late preclinical development, with an IND application expected in Q2 2021. Bristol-Myers Squibb aims to advance AGEN1777 for high-priority tumor indications like non-small cell lung cancer, highlighting its commitment to immuno-oncology.

Bristol Myers Squibb (NYSE: BMY) will participate in a fireside chat at the UBS Global Healthcare Virtual Conference on May 25, 2021. The session will feature David Elkins, CFO, and Samit Hirawat, Chief Medical Officer, answering questions about the company at 1 p.m. ET. Investors and the public can listen to the live webcast at investor.bms.com, and an archived version will be available later the same day.

Bristol Myers Squibb, a global biopharmaceutical company, focuses on developing innovative medicines for serious diseases.

Bristol Myers Squibb (BMY) reported results from the Phase 3 EXPLORER-HCM study of mavacamten, a cardiac myosin inhibitor for obstructive hypertrophic cardiomyopathy (oHCM), presented at ACC.21. After 30 weeks, patients treated with mavacamten experienced a significant improvement in the Kansas City Cardiomyopathy Questionnaire Overall Summary Score (KCCQ OSS) compared to placebo, with a mean difference of 9.1 points (p<0.001). A total of 36% of mavacamten patients achieved a clinically meaningful improvement (≥20 points) versus 15% in the placebo group. Results indicate significant potential for mavacamten in enhancing patient health status.

Bristol Myers Squibb (NYSE: BMY) presented significant research at the 2021 ASCO and EHA meetings, showcasing its commitment to addressing unmet needs in cancer and blood disorders. Findings from over 75 studies across 18 cancer types were highlighted, including durable survival benefits from Opdivo (nivolumab) and synergistic effects with Yervoy (ipilimumab). Key presentations featured the RELATIVITY-047 trial and CheckMate studies, indicating advancements in therapeutic combinations and cell therapies aimed at improving patient outcomes.

DarwinHealth has announced a collaboration with Bristol-Myers Squibb (BMY) for the Novel Cancer Target Initiative (NCTI). This initiative utilizes advanced quantitative systems biology to discover novel cancer targets across various tumor types. DarwinHealth will provide proprietary drug database insights to identify high-value cancer targets, which could lead to new anti-cancer therapies. The collaboration also builds on a previous partnership established in 2019 and includes upfront and milestone payments for DarwinHealth.

Bristol Myers Squibb (NYSE: BMY) will participate in a fireside chat at the 2021 Bank of America Securities Virtual Health Care Conference on May 11, 2021. Chris Boerner, Ph.D., Executive Vice President and Chief Commercialization Officer, will lead the discussion at 5 p.m. ET, addressing company matters. Investors and the public can listen via a live webcast at investor.bms.com. An archived version will be available the same day. This event provides an opportunity for stakeholders to gain insights into Bristol Myers Squibb's ongoing initiatives and market strategies.